A comparative analysis of the level of neuroactive amino acid glutamate in the blood serum of 17 healthy individuals and 63 patients with multiple sclerosis (MS), according to the course, stage and duration of the disease and disability, was performed. The level of glutamate was significantly higher in MS patients (16.47±4.37 nmol/μl) compared to healthy individuals (11.31±3.08 nmol/μl). It was increased by 43.4% in relapsing-remitting type of MS, by 45.3% in secondary progressive MS, and by 66.3% in primary progressive MS. In exacerbation of the disease, glutamate concentration reached maximum values (18.44±3.44 nmol/μl) compared to remission (15.12±3.97 nmol/μl). No significant changes in the levels of glutamate depending on the duration of illness and severity of disability were found. The obtained results can be used as one of additional diagnostic criteria for determining the disease stage, and control over the level of glutamate may become a new therapeutic target in MS.
Glutamate excitotoxicity in multiple sclerosis
- Authors: Ryazantseva A.A.1, Alifirova V.M.1, Ivanova S.A.2, Boyko A.S.2, Krotenko N.M.1
-
Affiliations:
- Siberian State Medical University, Ministry of Health
- Research Institute for Mental Health, Siberian Brunch of the Russian Academy of Medical Sciences
- Issue: Vol 7, No 2 (2013)
- Pages: 16-19
- Section: Original articles
- URL: https://journal-vniispk.ru/2075-5473/article/view/124567
- DOI: https://doi.org/10.17816/psaic240
- ID: 124567
Cite item
Full Text
Abstract
Keywords
About the authors
A. A. Ryazantseva
Siberian State Medical University, Ministry of Health
Author for correspondence.
Email: nervanastasia@mail.ru
Russian Federation, Tomsk
V. M. Alifirova
Siberian State Medical University, Ministry of Health
Email: nervanastasia@mail.ru
Russian Federation, Tomsk
S. A. Ivanova
Research Institute for Mental Health, Siberian Brunch of the Russian Academy of Medical Sciences
Email: nervanastasia@mail.ru
Russian Federation, Tomsk
A. S. Boyko
Research Institute for Mental Health, Siberian Brunch of the Russian Academy of Medical Sciences
Email: nervanastasia@mail.ru
Russian Federation, Tomsk
N. M. Krotenko
Siberian State Medical University, Ministry of Health
Email: nervanastasia@mail.ru
Russian Federation, Tomsk
References
- Бархатова В.П., Пантелеева Е.А., Алферова В.П. и др. Нейротрансмиттерные механизмы двигательных нарушений при рассеянном склерозе. Журн. неврол. и психиатрии им. С.С. Корсакова 2007; 2: 43–48.
- Бойко А.Н., Столяров И.Д., Сидоренко Т.В. и др. Патогенетическое лечение рассеянного склероза: настоящее и будущее. Журн. неврологии и психиатрии им. С.С. Корсакова 2009; 2: 90–99.
- Гусев Е.И., Завалишин И.А., Бойко А.Н. Рассеянный склероз. М.: Реал Тайм, 2011.
- Демакова Е.В. Изучение уровня нейротрансмиттеров в сыворотке крови у больных рассеянным склерозом. Объединенный научный журн. 2001; 20: 28–32.
- Завалишин И. А., Захарова М. Н. Рассеянный склероз: основные аспекты патогенеза. В кн: Е.И. Гусев, И.А. Завалишин, А.Н. Бойко (ред.). Рассеянный склероз и другие демиелинизирующие заболевания. М.: Миклош, 2004: 60–74.
- Иванова Е.М., Барабанова М.А., Музлаев Г.Г. и др. Аминокислоты в сыворотке крови у больных рассеянным склерозом. Журн. неврол. и психиатрии им. C.C. Корсакова 2012; 6: 50–54.
- Кротенко Н.М., Алифирова В.М., Рязанцева А.А. и др. Молекулы средней массы и антитела к нативной и денатурированной ДНК у пациентов при различных типах течения рассеянного склероза. Фундаментальные исследования 2012; 5: 305–310.
- Кротенко Н.В., Смирнова Л.П., Кротенко Н.М. и др. Окислительный стресс у пациентов с ремиттирующей и вторично-прогредиентной формами рассеянного склероза. Неврол. журн. 2010; 6: 26–29.
- Шмидт Т.Е., Яхно Н.Н. Рассеянный склероз. М.: Медицина, 2010.
- Bush W.S., DeJager P.L., Dudek S.M. et al. A knowledge-driven interaction analysis reveals potential neurodegenerative mechanism of multiple sclerosis susceptibility. Genes Immun. 2011; 12: 335–340.
- Callier S., Barcellos L.F., Baranzini S.E. et al. Osteopontin polymorphisms and disease course in multiple sclerosis. Genes Immun. 2008; 4: 312–315.
- Corthals A.P. Multiple sclerosis is not a disease of the immune system. Quart. Rev. Biol. 2011; 86: 287–321.
- Groom A.J., Smith T., Turski L. Multiple sclerosis and glutamate. Ann. NY Acad. Sci. 2003; 993: 229–275.
- Hughes S., Spelman T., Trojano M. et al. The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry. J. Neurol. Neurosurg. Psychiatry 2012; 83: 305–310.
- Kurtzke J.F. The diagnosis of multiple sclerosis (ed. C.M. Poser). NY: Thieme-Stratton, 1984: 3–13.
- McDonald W., Compston A., Edan G. et al. Recommended Diagnostic Criteria for Multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann. Neurol. 2010; 50: 121–127.
- Pin J.P. The metabotropic glutamate receptors: structure and functions. Neuropharmacology 2005; 34: 1–26.
- Popratiloff A., Weinberg R. AMPA receptor subunits underlying terminals of fine-caliber primary afferent fibers. J. Neurosci. 2006; 16: 3363–3372.
- Sarchielli P., Greco L., Floridi A. et al. Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid. Arch. Neurol. 2003; 60: 8: 1082–1088.
- Tovar K.R., Westbrook G.L. Mobile NMDA receptors at hippocampal synapses. Neuron 2002; 34: 255–264.
Supplementary files
